<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04224181</url>
  </required_header>
  <id_info>
    <org_study_id>2019P001220</org_study_id>
    <nct_id>NCT04224181</nct_id>
  </id_info>
  <brief_title>Inflammation and Cardiovascular Health in Women</brief_title>
  <official_title>Inflammation and Cardiovascular Health in Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Systemic immune activation and inflammation are believed to play a significant role in the
      development and clinical course of myocardial infarction (MI). Among women with HIV (WHIV),
      heightened systemic immune activation and inflammation persist, even when HIV infection is
      well-treated with contemporary antiretroviral therapeutic regimens. Moreover, WHIV in
      high-resource regions face a three-fold increased risk of myocardial infarction as compared
      with matched non-HIV-infected women. The goals of this study are to better understand ways in
      which HIV infection-incited systemic immune activation and inflammation augment MI risk among
      women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goals of this study are to better understand ways in which HIV infection-incited systemic
      immune activation and inflammation augment MI risk among women. To this end, WHIV and
      non-HIV-infected women will undergo structural and functional cardiovascular imaging studies
      (Cardiac PET, 99mTc-tilmanocept SPECT/CT, Contrast Enhanced Coronary and Aortic Computed
      Tomography Angiography) as well as vascular, metabolic/hormonal, and immune phenotyping.
      Measures of immune activation, arterial inflammation, and cardiovascular pathology will be
      compared between groups and interrelationships between these parameters will be assessed
      among WHIV.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Coronary flow reserve on Cardiac PET</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arterial inflammation on 99mTc-tilmanocept SPECT/CT</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atherosclerotic plaque on Contrast Enhanced Coronary and Aortic Computed Tomography Angiography</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional Flow Reserve</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of inflammation/immune activation</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of endothelial dysfunction</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of mitochondrial disease/dysfunction</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of myocardial stretch/injury</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormonal/metabolic parameters</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">65</enrollment>
  <condition>HIV/AIDS</condition>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Women with HIV</arm_group_label>
    <description>Individuals with female nascent sex who have been diagnosed with HIV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Women without HIV</arm_group_label>
    <description>Individuals with female nascent sex who do not have HIV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Cardiac PET</intervention_name>
    <description>A scan examining blood flow to the heart</description>
    <arm_group_label>Women with HIV</arm_group_label>
    <arm_group_label>Women without HIV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>99mTc-tilmanocept SPECT/CT</intervention_name>
    <description>A scan to look at inflammation in the arteries</description>
    <arm_group_label>Women with HIV</arm_group_label>
    <arm_group_label>Women without HIV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Contrast Enhanced Coronary and Aortic Computed Tomography Angiography</intervention_name>
    <description>A scan of the heart and surrounding blood vessels</description>
    <arm_group_label>Women with HIV</arm_group_label>
    <arm_group_label>Women without HIV</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, PBMCs, plasma, serum, endothelial cells
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        - Women with HIV and women without HIV
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        WHIV:

        Inclusion

          -  female nascent sex

          -  HIV

          -  age 40-79

          -  self-report of stable ART for at least 180 days prior to study entry - any regimen (no
             more than 30 days missed medication in the last 180 days)

        Exclusion

          -  self-reported history of MI, stroke, coronary revascularization

          -  stable or unstable angina symptoms

          -  a pre-existing diagnosis of diabetes, being actively treated with oral or injectable
             antihyperglycemic medication

          -  current cocaine use

          -  current use of exogenous oral, or transdermal, injected, or depot estrogen or
             testosterone

          -  current treatment with prescription, systemic (oral, IV, or IM) steroids, or
             anti-inflammatory/immune suppressant medical therapies (excluding topical therapies,
             UV therapy, ASA-derivative therapies, or NSAIDs) for autoimmune/inflammatory diseases
             (psoriasis, RA, IBD, lupus), post-transplant care, asthma, or pain syndromes

          -  use of oral steroids or prescription oral anti-inflammatory/immune suppressant
             medication for &gt;7 days within the past 30 days prior to entry

          -  pregnant or breastfeeding

          -  eGFR &lt; 60 ml/min/1.73 m2 calculated by CKD-EPI12

          -  known severe allergy to iodinated contrast media (CCTA), dextrans/DTPA/radiometals
             (99mTc-tilmanocept SPECT/CT), or regadenoson/adenosine (cardiac PET/CT).

          -  self-reported significant radiation exposure (&gt;2 CT angiograms) received within the
             past 12 months

          -  concurrent enrollment in conflicting research study.

        Non-HIV-infected women:

        As above, save for addition of inclusion criteria for negative HIV test and absent
        inclusion criteria for HIV and self-report of stable ART.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markella V. Zanni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Evelynne S Fulda, BA</last_name>
    <phone>617-724-0248</phone>
    <email>efulda@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Evelynne S Fulda, BA</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markella V Zanni, MD</last_name>
      <phone>617-724-6926</phone>
      <email>mzanni@mgh.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 8, 2020</study_first_submitted>
  <study_first_submitted_qc>January 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Markella V. Zanni,M.D.</investigator_full_name>
    <investigator_title>Associate Professor of Medicine, Harvard Medical School</investigator_title>
  </responsible_party>
  <keyword>Women</keyword>
  <keyword>Arterial Inflammation</keyword>
  <keyword>Systemic Immune Activation</keyword>
  <keyword>Endothelial Dysfunction</keyword>
  <keyword>Cardiovascular Disease Risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

